source
- FDA approves Mimrylo, a weekly injection for polycythemia vera, developed by Protagonist and sold by TakedaThe Food and Drug Administration has approved a new therapy for polycythemia vera, a rare blood cancer that causes an overproduction of red blood cells. The drug, known as rusfertide, will be mark…
- Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial missAstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…